March 9-12, 2020
Santa Clara Convention Center,
Santa Clara, California, USA
Revolutionize Cell Line Development & Engineering to Improve Product Quality, Reduce Timelines & Increase Titres
Leverage practical strategies to optimize CHO & novel cell lines, advance early clone selection & improve production of antibodies & complex molecules.
Advance your cell line development
Cell Line Engineering: Improving The Host Cell
- UC San Diego, Genentech, Pfizer, and Novartis will investigate the host cell; how do you manipulate established cell lines to achieve maximum results?
- Merck and Biogen Research will uncover the latest genetic engineering approaches, including CRISPR, and how they are being utilized.
- Overcome bioprocessing bottlenecks by engineering new host and vector designs.
- Consider impacts of cell line development on early and late stage bioprocessing.
Cell Line Development: Innovative Techniques & Technologies
- Identify the latest clonal selection strategies to reduce timelines and achieve a high-quality product.
- How are cutting-edge technologies being used in prediction, automation and high through-put approaches?
- Discover the benefits of novel cell lines and discuss the pros and cons with CHO. Get involved in the interactive panel discussion featuring Sutro Biopharma, Glycotope, Biogen, Octapharma, and UC Davis.
Coping with Clonal Stability & Complex Molecules
- Keynote speaker Kristin Neuman, CRISPR Patent Attorney, will get you up to date on the legal and regulatory requirements when developing cell lines.
- Achieve stable clones in an efficient and successful manner using genetic markers.
- What are the best techniques for manufacturing complex molecules and biosimilars outside of traditional antibodies?
Get the latest event updates
Industry Leaders and Academics Share Their Secrets to Success
Nathan Lewis, PhD
Associate Professor, Department of Pediatrics & Bioengineering
University of California, San Diego
Director CHO Cell Line Development
The Novo Nordisk Foundation Center for Biosustainability
The Leading Cell Line Development Meeting
Get Answers Now
- Are there constraints for commercial human therapeutic applications of gene editing, given the current IP landscape?
- How important is the outcome of the patent interference (UC – U of Vienna vs. “Boston Biotech Cluster”) to the future of gene editing?
- Are there uncertainties in translational research and clinical trials due to broad exclusive licenses over CRISPR technologies IP?
- Is CRISPR genome-editing know-how going to define future applications and further developments of it as nonobvious?
- Will commercial sublicenses be needed for follow-on applications of CRISPRC as technology? If so, when is this going to happen?
CONNECT WITH KEY BUYERS AT CELL LINE US 2020 IN SANTA CLARA
Whether you're increasing your company profile, launching a new product or focusing on new business development opportunities, collaborate with us to identify custom solutions to help you reach your goals.
(Companies A-L) Contact Jennifer Wickett: JWickett@knect365lifesciences.com | +1-857-504-6694
(Companies M-Z) Contact Blake Shuka: BShuka@knect365lifesciences.com | +1-857-504-6684